country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-151924

Copy Link Print Information

Antiviral agent 23

Antiviral agent 23 (compound 11b) is an antiviral agent to enterovirus 71 (EV71) with an EC₅₀ value of 94 nM. Antiviral agent 23 effectively suppresses the activity of METTL3/METTL14. Antiviral agent 23 can be used for the research of infection.

For research use only. We do not sell to patients.

CAS No.: 35940-03-5
Formula: C₁₈H₂₁N₅O₄
Molecular Weight:371.39

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (272 KB)

Antiviral agent 23 Chemical Structure

CAS No.: 35940-03-5

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
B16	IC₅₀	>166.7 μM Compound: 12	Antitumor activity against mouse B16 cells after 72 hrs by Calcein AM assay Antitumor activity against mouse B16 cells after 72 hrs by Calcein AM assay	[PMID: 17418578]
CCRF-CEM	IC₅₀	19.1 μM Compound: 12	Antitumor activity against human CEM cells after 72 hrs by Calcein AM assay Antitumor activity against human CEM cells after 72 hrs by Calcein AM assay	[PMID: 17418578]
G-361	IC₅₀	>166.7 μM Compound: 12	Antitumor activity against human G361 cells after 72 hrs by Calcein AM assay Antitumor activity against human G361 cells after 72 hrs by Calcein AM assay	[PMID: 17418578]
HeLa	CC₅₀	>100 μM Compound: 11b	Cytotoxicity against human HeLa cells by MTS assay Cytotoxicity against human HeLa cells by MTS assay	[PMID: 36455356]
HL-60	IC₅₀	6.4 μM Compound: 12	Antitumor activity against human HL60 cells after 72 hrs by Calcein AM assay Antitumor activity against human HL60 cells after 72 hrs by Calcein AM assay	[PMID: 17418578]
HOS	IC₅₀	>166.7 μM Compound: 12	Antitumor activity against human HOS cells after 72 hrs by Calcein AM assay Antitumor activity against human HOS cells after 72 hrs by Calcein AM assay	[PMID: 17418578]
K562	IC₅₀	>166.7 μM Compound: 12	Antitumor activity against human K562 cells after 72 hrs by Calcein AM assay Antitumor activity against human K562 cells after 72 hrs by Calcein AM assay	[PMID: 17418578]
NIH3T3	IC₅₀	>166.7 μM Compound: 12	Cytotoxicity against mouse NIH 3T3 cells after 72 hrs by Calcein AM assay Cytotoxicity against mouse NIH 3T3 cells after 72 hrs by Calcein AM assay	[PMID: 17418578]
RD	CC₅₀	>100 μM Compound: 11b	Cytotoxicity against human RD cells by MTS assay Cytotoxicity against human RD cells by MTS assay	[PMID: 36455356]
Vero	CC₅₀	>100 μM Compound: 11b	Cytotoxicity against african green monkey Vero cells by MTS assay Cytotoxicity against african green monkey Vero cells by MTS assay	[PMID: 36455356]
Vero C1008	CC₅₀	>100 μM Compound: 11b	Cytotoxicity against african green monkey Vero E6 cells by MTS assay Cytotoxicity against african green monkey Vero E6 cells by MTS assay	[PMID: 36455356]

In Vitro

Antiviral agent 23 (0-100 μM) inhibits CVA21 and EV68 replication in HeLa cells with EC₅₀ values of 36.4 and 8.9 μM, respectively^[1].
Antiviral agent 23 (100 μM) inhibits the enzymatic activity of METTL3/METTL14 of 74.45%^[1].
Antiviral agent 23 (0-100 μM) shows antiviral effect to EV71 and inhibits the replication of the EV71 strain BrCr in RD cells with an EC₅₀ value of 94 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Chemical Information

CAS No. 35940-03-5
Molecular Weight 371.39
Formula C₁₈H₂₁N₅O₄
SMILES

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=CN=C3NCC4=CC=CC(C)=C4)=C3N=C2)O1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocols

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Salerno M, et al. Rational design of novel nucleoside analogues reveals potent antiviral agents for EV71. Eur J Med Chem. 2022 Nov 24;246:114942. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote